Previous studies have indicated that the δ-carboline (2) ring system derived from the natural product cryptolepine (1) may represent a pharmacophore for anti-infective activity. This paper describes the design and synthesis of a small library of substituted δ-carbolines and the evaluation of the anti-fungal and anti-bacterial activities. An evaluation of the anti-bacterial activity of a previously reported library of ring-opened analogs was also conducted to provide an opportunity to test the hypothesis that both group of compounds may have the same biological target. Results indicate that against a selected group of fungal pathogens, substituted δ-carbolinium analogs displayed higher potency and several fold lower cytotoxicity than cryptolepine the parent natural product. Both the δ-carbolinium compounds and their ring-opened analogs, exhibited equally high anti-bacterial activity against the selected pathogens and especially against the gram positive bacteria evaluated. Published by Elsevier Masson SAS.
Previous studies have indicated that the δ-carboline (2) ring system derived from the natural product cryptolepine (1) may represent a pharmacophore for anti-infective activity. This paper describes the design and synthesis of a small library of substituted δ-carbolines and the evaluation of the anti-fungal and anti-bacterial activities. An evaluation of the anti-bacterial activity of a previously reported library of ring-opened analogs was also conducted to provide an opportunity to test the hypothesis that both group of compounds may have the same biological target. Results indicate that against a selected group of fungal pathogens, substituted δ-carbolinium analogs displayed higher potency and several fold lower n class="Disease">cytotoxicity than cryptolepine the parent natural product. Both the δ-carbolinium compounds and their ring-opened analogs, exhibited equally high anti-bacterial activity against the selected pathogens and especially against the gram positive bacteria evaluated. Published by Elsevier Masson SAS.
Authors: S G Franzblau; R S Witzig; J C McLaughlin; P Torres; G Madico; A Hernandez; M T Degnan; M B Cook; V K Quenzer; R M Ferguson; R H Gilman Journal: J Clin Microbiol Date: 1998-02 Impact factor: 5.948
Authors: Comfort A Boateng; Suresh V K Eyunni; Xue Y Zhu; Jagan R Etukala; Barbara A Bricker; M K Ashfaq; Melissa R Jacob; Shabana I Khan; Larry A Walker; Seth Y Ablordeppey Journal: Bioorg Med Chem Date: 2010-11-10 Impact factor: 3.641
Authors: Guoyi Ma; Shabana I Khan; Melissa R Jacob; Babu L Tekwani; Zuqiang Li; David S Pasco; Larry A Walker; Ikhlas A Khan Journal: Antimicrob Agents Chemother Date: 2004-11 Impact factor: 5.191
Authors: Xue Y Zhu; Leroy G Mardenborough; Shouming Li; Abdul Khan; Wang Zhang; Pincheng Fan; Melissa Jacob; Shabana Khan; Larry Walker; Seth Y Ablordeppey Journal: Bioorg Med Chem Date: 2006-11-01 Impact factor: 3.641
Authors: Leroy G Mardenborough; Xue Y Zhu; Pincheng Fan; Melissa R Jacob; Shabana I Khan; Larry A Walker; Seth Y Ablordeppey Journal: Bioorg Med Chem Date: 2005-06-02 Impact factor: 3.641
Authors: Sidney Bolden; Xue Y Zhu; Jagan R Etukala; Comfort Boateng; Tryphon Mazu; Hernan Flores-Rozas; Melissa R Jacob; Shabana I Khan; Larry A Walker; Seth Y Ablordeppey Journal: Eur J Med Chem Date: 2013-10-05 Impact factor: 6.514
Authors: Sidney Bolden; Comfort A Boateng; Xue Y Zhu; Jagan R Etukala; Suresh K Eyunni; Melissa R Jacob; Shabana I Khan; Seth Y Ablordeppey Journal: Bioorg Med Chem Date: 2013-09-03 Impact factor: 3.641